Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 7, 2014, Pages 727-730

  Taymans, Jean Marc ^a  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Kinase inhibitor; Leucine rich repeat kinase 2; Parkinson's disease; Phenotypic assay

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LEUCINE RICH REPEAT KINASE 2 INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG; LRRK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

AUTOPHOSPHORYLATION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LONG TERM CARE; NONHUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; PHENOTYPE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; ANTAGONISTS AND INHIBITORS;

HUMANS; PARKINSON DISEASE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 84903143726     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.915945     Document Type: Review

References (20)

1. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011;91:1161-218
2. Paisan-Ruiz C, Jain S, Evans EW, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004;44:595-600 (Pubitemid 39531224)
3. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-7 (Pubitemid 39531225)
4. Gasser T. Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009;11:e22
5. Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009;41:1303-7
6. Simon-Sanchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009;41:1308-12
7. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010;11:791-7
8. Vancraenenbroeck R, Lobbestael E, De Maeyer M, et al. Kinases as targets for Parkinson's disease; from genetics to therapy. CNS Neurol Disord Drug Targets 2011;10:724-40
9. Kethiri RR, Bakthavatchalam R. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011-2013). Expert Opin Ther Pat 2014;24:745-57
10. Deng X, Choi HG, Buhrlage SJ, et al. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006-2011). Expert Opin Ther Pat 2012;22:1415-26
11. Baptista MA, Dave KD, Frasier MA, et al. Loss of leucine-rich repeat kinase 2 (LRRK2) in rats leads to progressive abnormal phenotypes in peripheral organs. PLoS One 2013;8:e80705
12. Herzig MC, Kolly C, Persohn E, et al. LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice. Hum Mol Genet 2011;20:4209-23
13. Dzamko N, Deak M, Hentati F, et al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser (935), disruption of 14-3-3 binding and altered cytoplasmic localization. Biochem J 2010;430:405-13
14. Lobbestael E, Zhao J, Rudenko IN, et al. Identification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycle. Biochem J 2013;456:119-28
15. Daniëls V, Baekelandt V, Taymans JM. On the Road to Leucine-Rich Repeat Kinase 2 Signalling: evidence from Cellular and in vivo Studies. Neurosignals 2011;19:1-15
16. Ramonet D, Daher JP, Lin BM, et al. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One 2011;6:e18568
17. Chen CY, Weng YH, Chien KY, et al. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ 2012;19:1623-33
18. Lee BD, Shin JH, VanKampen J, et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010;16:998-1000
19. Dusonchet J, Kochubey O, Stafa K, et al. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2. J Neurosci 2011;19;31:907-12
20. Burke RE, O'Malley K. Axon degeneration in Parkinson's disease. Exp Neurol 2013;246:72-83.